Clinical evaluation of natalizumab for formulary consideration

Expert Opinion on Biological Therapy
Ashley BivinsFadia T Shaya

Abstract

Natalizumab is a monotherapy for relapsing forms of multiple sclerosis (MS) and maintaining remission in Crohn's disease (CD). Evaluation of natalizumab's clinical relevance must be performed before considering its place in treatment of these diseases. MEDLINE and PubMed searches were performed using the keywords multiple sclerosis, Crohn's disease, natalizumab and clinical trials. The manufacturer's product information was consulted to extract additional data. Pivotal clinical trials included: Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM), Safety and Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing Remitting Multiple Sclerosis (SENTINEL), Efficacy of Natalizumab as Active Crohn's Therapy (ENACT)-1 and 2 and Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE). AFFIRM and SENTINEL showed improvements in progression of MS. ENACT-1 failed to show a significant effect, but the follow-up trials ENACT-2 and ENCORE were able to demonstrate a response to natalizumab. Two trials on efficacy of Tysabri for treatment of MS demonstrated positive results. Efficacy for CD was mixed. More research demonstrating head-to-head evidence against ot...Continue Reading

References

Feb 1, 1991·Journal of Neuroscience Research·W F HickeyH Kimura
Jun 6, 1996·The New England Journal of Medicine·P S Frenette, D D Wagner
Jul 4, 1996·The New England Journal of Medicine·P S Frenette, D D Wagner
Sep 23, 2000·European Journal of Radiology·K KarlingerZ Tarján
Sep 28, 2000·The New England Journal of Medicine·J H NoseworthyB G Weinshenker
Apr 17, 2002·Lancet·Alastair Compston, Alasdair Coles
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Jan 3, 2003·The New England Journal of Medicine·Ulrich H von Andrian, Britta Engelhardt
May 13, 2003·Clinical Cornerstone·Kandice L Knigge
Dec 11, 2003·Multiple Sclerosis : Clinical and Laboratory Research·Alireza Minagar, J Steven Alexander
Aug 13, 2004·Gut·M J CarterUNKNOWN IBD Section, British Society of Gastroenterology
Apr 28, 2005·Expert Review of Neurotherapeutics·Richard A Rudick, Alfred Sandrock
May 10, 2005·Postgraduate Medical Journal·S M LearyA J Thompson
Jun 11, 2005·The New England Journal of Medicine·Annette Langer-GouldDaniel Pelletier
Jun 11, 2005·The New England Journal of Medicine·B K Kleinschmidt-DeMasters, Kenneth L Tyler
Nov 4, 2005·The New England Journal of Medicine·William J SandbornUNKNOWN Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group
Dec 6, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·F SellebjergUNKNOWN EFNS Task Force on Treatment of Multiple Sclerosis Relapses
Mar 3, 2006·The New England Journal of Medicine·Chris H PolmanUNKNOWN AFFIRM Investigators
Mar 3, 2006·The New England Journal of Medicine·Richard A RudickUNKNOWN SENTINEL Investigators
Mar 3, 2006·The New England Journal of Medicine·Tarek A YousryDavid B Clifford
Nov 25, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Catherine MassartGilles Edan
May 9, 2007·Gastroenterology·Stephan R TarganUNKNOWN International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group
Jan 22, 2008·Lancet Neurology·Aaron BosterUNKNOWN Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine
Sep 18, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·I ElovaaraUNKNOWN EFNS
Mar 4, 2009·Neurology·A D GoodmanUNKNOWN GLANCE Investigators
Aug 12, 2009·Journal of Neurovirology·Roisin M LonerganNiall J Tubridy
Sep 11, 2009·The New England Journal of Medicine·Eugene O Major
Sep 11, 2009·The New England Journal of Medicine·Hans LindåClaes Martin
Feb 2, 2010·Lancet Neurology·Richard M Ransohoff
Feb 23, 2010·Lancet Neurology·Devon Conway, Jeffrey A Cohen

❮ Previous
Next ❯

Citations

Jan 31, 2015·Scandinavian Journal of Gastroenterology·Javier P Gisbert, María Chaparro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
A B OturaiP S Sorensen
Revista de neurologia
A Horga, J F Horga de la Parte
Journal of the Neurological Sciences
Norman PutzkiHans Christoph Diener
© 2021 Meta ULC. All rights reserved